RESEARCH ARTICLE

Intraoperative Fluorescence Imaging of Peripheral and Central Nerves Through a Myelin-Selective Contrast Agent

Victoria E. Cotero, Tiberiu Siclovan, Rong Zhang, Randall L. Carter, Anshika Bajaj, Nicole E. LaPlante, Evgenia Kim, Daniel Gray, V. Paul Staudinger, Siavash Yazdanfar, Cristina A. Tan Hehir

GE Global Research, One Research Circle, Niskayuna, NY, 12309, USA

Abstract

Purpose: Patients suffer from complications as a result of unintentional nerve damage during surgery. We focus on improving intraoperative visualization of nerves through the use of a targeted fluorophore and optical imaging instrumentation.

Procedure: A myelin-targeting fluorophore, GE3111, was synthesized, characterized for its optical and myelin-binding properties using purified myelin basic protein, and evaluated in mice. Additionally, a compact instrument was adapted to visualize nerves.

Results: GE3111 was synthesized using a versatile methodology. Its optical properties were sensitive to the local environment both in vitro and in vivo. Following intravenous injection, central and peripheral nerves were visualized, with the kinetics of nerve uptake modifiable depending on the formulation. Fluorescence polarization showed specific and strong binding to purified myelin basic protein. Nerves were visualized in vivo using a dedicated compact imaging device requiring less than 2.5 mW/cm² of illumination at 405 nm.

Conclusions: Fluorescence imaging of nerves through myelin showed a potential for use in image-guided surgery. Intraoperative nerve imaging is an example where contrast agent and instrument development come together as a result of clinical need.

Key Words: Image-guided surgery, Nerves, Myelin, Fluorescence, Compact instrumentation

Introduction

Iatrogenic damage to peripheral nerves is a major cause of morbidity associated with many surgical procedures, including prostatectomy [1–4], coronary artery bypass graft [5–7], thyroidectomy [8, 9], rhytidectomy [10], and breast cancer surgery [11–13]. Symptoms associated with nerve damage are dependent upon the location, type of nerve, and the severity of the damage, and may result in loss of function, weakness, muscle atrophy, fasciculation, paralysis, cardiac irregularities, allodynia, and chronic neuropathy [14]. The cause of nerve damage during open and laparoscopic surgical procedures is variable but is often the result of inadvertent surgical damage due to poor visibility of the nerve as compared to surrounding tissues or an unfortunate necessity due to close proximity of the nerve to target structures [15]. Currently, most surgical procedures are performed without image guidance, as available technologies lack the specificity needed to provide nerve-selective imaging [16]. Applied nerve-sparing procedures generally rely on anatomical landmark identification and are

Electronic supplementary material The online version of this article (doi:10.1007/s11307-012-0555-1) contains supplementary material, which is available to authorized users.

Correspondence to: Cristina Tan Hehir; e-mail: tanhehir@research.ge.com
highly dependent on the surgeon’s skill and experience. In addition to visual identification, intraoperative electrical stimulation devices are often employed to verify continued stimulation, via nerve, of the muscle or organ in question [17, 18]. However, there are inherent limitations to relying on these methods alone. Visual identification of nerves can be inconsistent due to the intricacy and size of the individual nerves, and overall variation in the anatomic location across patient populations [19]. Furthermore, intraoperative electrical stimulation fails to prevent nerve damage; rather, it identifies damage that has already occurred. Thus, optical imaging could provide a valuable clinical tool for image-guided surgery by allowing direct and real-time visualization of nerves.

We have previously reported the generation of a nerve-specific fluorophore, 4-[(1E)-2-[4-[(1E)-2-[4-aminophenyl] ethenyl]-3-methoxyphenyl] ethenyl]-benzonitrile (GE3082), that crosses the blood–nerve and blood–brain barriers, producing significant fluorescence in myelinated nerves after a single systemic injection [20]. Because of its lipophilic nature, GE3082 requires a specialized intravenous formulation consisting of 65 % serum, 20 % HEPES, 10 % dimethyl sulfoxide (DMSO), and 5 % Cremophor EL to maintain aqueous solubility, and thus, it is non-ideal for clinical intravenous use due to the potential negative physiologic and pharmacologic effects arising from this formulation [21, 22].

The goal of our study is to advance the current understanding of myelin-targeting fluorophores and to demonstrate in vivo imaging of nerves during surgery. We describe here the in vitro and in vivo characterization of a newly synthesized fluorophore, 1-methyloxanol-4-[(1E)-2-[4-[(1E)-2-[4-aminophenyl] ethenyl]-3-methoxyphenyl] ethenyl]-benzene (GE3111). GE3111 was made using a more versatile synthetic methodology with reduced number of steps and more amenable to creating chemical libraries by parallel synthesis. GE3111 had improved aqueous solubility as well as reduced lipophilicity compared with GE3082, allowing for the development of more clinically relevant formulations for intravenous injection. We also describe advancements in the understanding of the myelin-targeting binding interaction, pharmacodynamics, pharmacokinetics, and environmental influences on the optical properties of this fluorophore.

Materials and Methods

Synthesis of GE3111

GE3111 was synthesized in a stepwise procedure as shown in Fig. 1. Heck coupling [23] of 4-bromo-3-methoxybenzaldehyde [24] with Boc-protected 4-amino styrene in the presence of the water-soluble TPPTS catalyst proceeded in 70 % yield after purification, to give stilbene aldehyde 2. Subsequent olefination [25] with the phosphonate 3 proceeded in 65 % yield after purification to give bis-stilbene 4, exclusively in the trans–trans configuration [26]. Deprotection with trifluoroacetic acid (TFA) in amylene-containing dichloromethane, gave the desired dye 5 in essentially quantitative yield and better than 95 % purity by nuclear magnetic resonance (NMR) spectroscopy. Removal of traces of fluorescent impurities was achieved through a final purification by reverse phase chromatography, eluting with water–acetonitrile gradient containing 0.1 % v/v TFA. The dye was found to be more stable upon storage as its TFA salt; whenever free base dye was needed, a simple aqueous workup (NaHCO₃/dichloromethane) supplied the required dye as >99.9 % purity. Details of the synthetic methodology can be found in the Supplementary Material.

Physical and Optical Properties of GE3111

A 10 mM stock solution of GE3111 was prepared in anhydrous dimethylsulfoxide (DMSO) to ensure complete dissolution of the fluorophore. Subsequent aliquots of the stock solution were taken to prepare 10 μM solutions of GE3111 in the following solvents: toluene, olive oil, DMSO, water, and a selected intravenous (IV) formulation (58.5 % distilled water, 30 % 2-hydroxypropyl-β-cyclodextrin, 10 % propylene glycol, 1 % PEG-300, and 0.5 % DMSO). Absorbance spectra were taken using a Lambda 20 UV/Vis spectrometer (Perkin Elmer, Waltham, MA). The wavelength of maximum absorbance was then used as the excitation wavelength for the collection of the fluorescence emission spectra on a steady-state fluorimeter (Photon Technology International, Birmingham, NJ). The molar extinction coefficient (ε) for GE3111 was calculated at the maximum excitation wavelength respective to each solvent, using Beer–Lambert’s law. The quantum yield (QY) values of GE3111 in each solvent were measured in comparison to the fluorescence emission of a known standard, coumarin-6 (QY = 78 % [27]), using the single-point method [28].

The logD values of GE3082 and GE3111 at pH 7.4 were calculated using Accelrys Discovery Studio software (San Diego, CA). Maximum solubility was estimated by dissolution of an excess of either GE3111 or GE3082 in formulation (58.5 % distilled water, 30 % 2-hydroxypropyl-β-cyclodextrin, 10 % propylene glycol, 1 % PEG-300, and 0.5 % DMSO), followed by centrifugation (10 min, 10,000×g). The supernatant was diluted at least 1,000-fold in DMSO, and its absorption spectrum was taken. Concentration was calculated using Beer–Lambert’s equation, with ε equal to 72,820 and 41,800 M⁻¹ cm⁻¹ for GE3111 and GE3082, respectively. Dynamic light scattering (DLS) spectroscopy was used to estimate the dispersity of the formulated fluorophores, detailed of which are in the Supplementary Material.

Myelin Basic Protein Binding Assay

Purified native myelin basic protein (MBP) was obtained from Prof. Paolo Riccio, University of Bari, and was isolated from bovine brain using a published protocol [29]. Details of the fluorescence polarization binding assay will be published elsewhere (Bajaj et al., manuscript in preparation). Briefly, the binding assay reaction was prepared by incubating increasing amounts of native MBP with 100 nM of GE3111 in a 96-well plate. Protein and fluorophore dilutions were made with 0.25 % CHAPS in 20 mM Tris, pH 7.2, which also served as the binding buffer. The reagents were allowed to incubate at room temperature for 10 min; after which, the raw fluorescence intensities parallel (P) and perpendicular (S) to the excitation plane were measured using the fluorescence polarization
mode of a Spectra Max M5 plate reader (Molecular Devices, Sunnyvale, CA) at 400 nm excitation and 540 nm emission.

Anisotropy was calculated using the equation $\frac{S_{-1} - S_{-2}}{S_{+1}}$.

Data fitting was performed via non-linear regression using SigmaPlot software (Version 11.2) to obtain the $K_d$ value.

In Vivo Fluorescence Imaging

Instrumentation *In vivo* imaging consisted of detailed fluorescence emission characterization and surgical imaging using either a Zeiss Lumar imaging system (Carl Zeiss Inc. Thornwood, NY) with coupled multispectral imaging camera (Nuance camera; CRI, Woburn, MA) or a custom compact surgical imaging instrument.

The Zeiss Lumar imaging instrument was used in both the dosing and kinetics studies. A filter centered at 406 nm with a 15-nm bandwidth was used for excitation of the fluorophore. Fluorescence emission data were then recorded at wavelengths ranging from 420 to 720 nm at 10 nm steps using the attached multispectral camera. Fluorescence images were collected using exposure times of 5 s in both control and fluorophore injected animals for normalization. Numerical data presented herein represent the area under the curve for fluorescence emission covered roughly half of the visible spectrum, white light video of the surgical field was not recorded during intraoperative imaging.

Animals All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at GE Global Research. Male CD-1 mice ranging in body weight from 25–30 g were purchased from Charles River Laboratories (Wilmington, MA) and housed at 22–23 °C on a 12 h light/dark cycle. Mice were maintained on Prolab RMH 3500 mouse chow (LabDiet Framingham, MA) and water *ad libitum*. On the day of the experiment, mice were anesthetized using 2–4 % isoflurane and given a single tail vein injection of either GE3111 in formulation or formulation excipients alone. The mice were then returned to the home cage until the designated time-point for imaging.

Formulation of GE3111 for Intravenous Administration GE3111 was prepared for intravenous (IV) administration by dissolving in a buffer containing 0–0.5 % DMSO (Sigma D8418), 10–35 % propylene glycol (Fisher P3551), 1–35 % polyethylene glycol (PEG-300; Sigma 202371), 0–30 % 2-hydroxypropyl-β-cyclodextrin (2-HPβCD, Sigma H5784), and 29.5–58.5 % sterile water (Sigma W3500). The IV formulation was brought to a final pH of 4.5 using 1M HCl. No preservative system was used as formulated doses were injected on the same day. Complete solubility of the agent in the formulation mixture was verified using (1) visual observation for particulates, (2) centrifugation (5 min, 10,000 × g) followed by observation, (3) dissolution in a physiologically relevant buffer (e.g., Sorenson's phosphate buffer) followed by visual observation and UV/Vis analysis, and (4) assessment of sedimentation and particle size using DLS.

Dosing and Kinetics The dose–response and kinetics for GE3111 was determined in adult male CD-1 mice. In the dose–response study, each animal received a single dose of GE3111 4 h prior to imaging of key nerves. Doses of GE3111 in this study ranged from 0.46 to 16.67 mg/kg. Control mice were given a single injection of the IV formulation (vehicle only) and measured to determine background fluorescence. Post-processing of imaging data included line profile analysis to determine the fluorescence maxima of nerves and adjacent muscle and adipose tissue sample. The fluorescence...
maxima were measured in two regions of each nerve and surrounding tissue to display the average nerve-to-muscle ratio (N:M). Three mice at each dose were evaluated.

For the kinetics study, each mouse received a single injection of 3.77 mg/kg GE3111 and was euthanized at 1, 2, 3, 4, 12, and 24 h post-injection. Key nerves were then dissected and imaged. Control mice used were given a single injection of IV formulation only. Three mice at each time-point were evaluated.

**Results**

**Synthesis and In Vitro Properties of GE3111**

GE3111 was synthesized using a more direct and versatile methodology compared to what was previously described for BMB, GE3081, and GE3082 [20, 31]. This method consisted of a tandem Heck coupling followed by a Horner–Wittig olefination using commercially available bromoaldehyde for the middle ring and readily available building blocks for the terminal rings (Fig. 1).

GE3111 has a molecular weight of 405 g/mole and a logD value at pH 7.4 of 4.5, which is half a log unit lower than that of GE3082 (Table 1). The maximum solubility in the IV formulation buffer, consisting of 58.5 % distilled water, 30 % 2-HPβCD, 10 % propylene glycol, 1 % PEG-300, and 0.5 % DMSO, was estimated using UV/Vis spectroscopy. Under the same conditions, the maximum solubility of GE3111 was about six times more than GE3082 (Table 1).

To investigate how local environment affects optical properties, we recorded the spectroscopic properties in a series of solvents varying in polarity. In general, GE3111 showed a bathochromic shift in fluorescence emission spectra with increasing solvent polarity, similar to GE3082 (Table 2, Fig. 2a, b). Moreover, a significant increase in quantum yield was observed with decreasing solvent polarity. For example, the more polar solvent DMSO exhibited a ~100 nm red-shift in fluorescence emission and a five-fold decrease in quantum yield compared to the least polar solvent, toluene.

**Specificity of GE3111 for Purified Myelin Basic Protein**

Although myelin has been suggested as the binding target for GE3082 [20], little is known as to the exact specificity of these fluorophores for MBP, a major protein component of myelin. The affinity of GE3111 to native MBP was determined using a fluorescence polarization-based binding assay that measured the anisotropy of a fixed concentration of GE3111 (100 nM) either in the absence or presence of increasing concentrations of purified MBP.

### Table 1. Physical characterization of GE3111 and GE3082

| Agent   | Structure | Solubility (mM) | LogD |
|---------|-----------|-----------------|------|
| GE3082  | ![GE3082 Structure](image) | 8.6            | 5.0  |
| GE3111  | ![GE3111 Structure](image) | 51.5           | 4.5  |

*Maximum solubility when formulated in 58.5 % distilled water, 30 % 2-HPβCD, 10 % propylene glycol, 1 % PEG-300, and 0.5 % DMSO.

### Table 2. Solvent dependence of the optical properties of GE3111

| Solvent (D.C.) | ε (M⁻¹ cm⁻¹) | Ex max (nm) | Em max (nm) | QY (%) |
|----------------|--------------|-------------|-------------|-------|
| Water (80)     | 19,680       | 362         | 590         | 0.1   |
| DMSO (46.7)    | 72,820       | 412         | 629         | 1.0   |
| Olive oil (3.1)| 17,700       | 382         | 521         | 4.8   |
| Toluene (2.4)  | 17,680       | 402         | 527         | 5.3   |
| IV formulation (not determined) | 60,840 | 396 | 594 | 1.5 |

*ε molar extinction coefficient, Ex max excitation maximum wavelength, Em max emission maximum wavelength, QY quantum yield

*Dielectric constant, values from http://macro.lsu.edu/ and http://orioninstruments.com/html/tools/dielectric.aspx

*Contained 58.5 % distilled water, 30 % 2-HPβCD, 10 % propylene glycol, 1 % PEG-300, and 0.5 % DMSO
native MBP. Unbound GE3111 in buffer had an anisotropy value of 0.250. Incubation of GE3111 with increasing concentrations of MBP caused a corresponding increase in the anisotropy values that saturate out at 0.321 (Fig. 2c), suggesting slower rotation of GE3111 due to a binding interaction between GE3111 and MBP. The anisotropy data were mathematically fitted, resulting in a dissociation constant ($K_d$) of $15 \pm 10$ nM, indicating a strong affinity of the fluorophore for MBP. Details of the binding assay will be published elsewhere (Bajaj et al., manuscript in preparation).

**In Vivo Fluorescence Imaging**

Initial nerve *in vivo* imaging was performed using a CRI-Nuance multispectral camera to assess the overall spectral differences among tissue types. Following *in vivo* characterization of GE3111 in mice, the overall feasibility of real-time nerve visualization in an intraoperative setting was demonstrated by recording live video during a surgical dissection of a GE3111-labeled mouse nerve using a compact instrument built in-house.

GE3111 fluorescence was observed in mouse nerves containing myelin such as brachial plexus, trigeminal, optic, sciatic, facial, femoral, vagus, phrenic, median, radial, supracapular, and laryngeal nerves as well as the brain and spinal column. Fluorescence was also observed in adipose tissue. Representative images collected from sciatic nerves, trigeminal, and optic nerves labeled *in vivo* with either formulation buffer-only (control) or GE3111 are shown in Fig. 3a–c. Cross-sectional analysis of the control and GE3111-labeled sciatic nerve is shown in Fig. 3d, e. Specific labeling of the myelin sheath surrounding the nerve and not the surrounding connective tissue was observed with GE3111. Multispectral imaging showed that while the fluorescence intensity in adipose tissue was high, the emission wavelength of GE3111 in adipose tissue was blue-shifted (emission maximum at 550 nm, Fig. 3f) compared to that in peripheral and central nervous tissue (emission maximum at 590–600 nm). Visually, the nerves appeared red-orange, while the adipose tissue appeared yellow-green. The surrounding muscle tissue was dark.

**Dose and Kinetics of GE3111** The dose–response and kinetics for GE3111 were evaluated in mice. In the dose–response study, mice received a single injection of GE3111 in concentrations ranging from 0.46 to 16.67 mg/kg formulated in 58.5 % distilled water, 30 % 2-HPβCD, 10 % propylene glycol, 1 % PEG-300, and 0.5 % DMSO. Control mice were given a single injection of IV formulation buffer only to assess background fluorescence. Four hours after injection, mice were euthanized, and the sciatic nerves were exposed by removal of biceps femoris. Example images of sciatic nerves with different doses of GE3111 are shown in Fig. 4a–c. Post-processing of images using line profile analysis was performed to determine fluorescence maxima in the sciatic nerve and adjacent muscle and adipose. Fluorescence emission intensity increased in the sciatic nerve up to a concentration of 6.67 mg/kg. There was no significant change in fluorescence intensity in concentrations greater than 6.67 mg/kg, suggesting a saturation of binding to MBP at these concentrations. However, fluorescence emission in adipose tissue showed no indications of saturation consistent with lack of specific binding target (Fig. 4d). Minimal fluorescence was seen in adjacent muscle tissue. Finally, all...
concentrations measured in the dose–response relationship exhibited a nerve-to-muscle ratio (N:M) greater than the control (Fig. 4e).

Based on the dose–response study, a theoretical half maximal dose of GE3111 was calculated to be 3.77 mg/kg. This dose was then used to assess the kinetics of GE3111 in vivo by measuring the fluorescence in nerve at the following time-points: 1, 2, 3, 4, 12, and 24 h post-IV injection. Control mice received a single injection of formulation buffer only. Maximum muscle fluorescence was observed at 1 h post-IV injection, resulting in a nerve to muscle ratio of 0.95±0.12 (Fig. 5a, b). The overall fluorescence in muscle decreased consecutively following the 1-h time-point. As muscle fluorescence decreased, the overall fluorescence in nerve and adipose increased, reaching a maximum at 4 h post-IV injection (N:M=3.1±0.10; Fig. 5a, b). No fluorescence was seen in control mice (data not shown). After 4 h, fluorescence emission decreased dramatically in all tissues. At 12 h post-IV injection, no visible fluorescence was present in nerve and adjacent muscle. However, minimal fluorescence was still visible in adipose tissue. This could be due to the presence of higher fluorescence intensity in adipose tissue to begin with or slower clearance from adipose tissue due to its poorly perfused nature as compared to other peripheral tissues [32]. No animals were used for more than one time-point to prevent aberrant data resulting from anesthesia and/or surgically induced changes in pharmacokinetics and pharmacodynamics.

GE3111 reached a maximum fluorescence in nervous tissue at 4 h post-IV injection as shown previously (Fig. 5a, b). However, modifications in formulating the buffer components can be utilized to either increase or decrease the overall kinetics in vivo. In these experiments, 3.77 mg/kg of GE3111 was administered in varied formulation protocols. These formulation protocols included usage of concentrations of 2-HPβCD ranging from 0 % to 30 % and increasing concentrations of propylene glycol and PEG-300, used to compensate for decreases in solubility. No animal was used for measurements deriving from more than a single formulation at any set time-point. At 1 h post-IV injection, fluorescence emission was highest in the 0 % and 2 % 2-HPβCD formulation compared with values obtained using 10 % and 30 % 2-HPβCD (Fig. 5c). GE3111 formulated in 30 % 2-HPβCD had maximal N:M at 4 h post-IV injection, but had a maximal N:M at 1 h post-IV injection when formulated at 0 % 2-HPβCD (Fig. 5d). These results suggest

![Multispectral imaging of GE3111 in vivo](image)

Fig. 3. Multispectral imaging of GE3111 in vivo. Images were recorded 4 h post-IV administration of a 16.67 mg/kg dose. Representative fluorescence images of a mouse sciatic nerve (a) and optic and trigeminal nerves (b) are shown. Nerve location in each image is indicated by an arrow (light white for sciatic nerve, heavy white for trigeminal nerves, yellow for optic nerves), and adjacent tissue structures such as adipose (A) and brain (Br) are annotated. Mice receiving only a single injection of formulation excipients only (no GE3111) were included as control (c). A cross-sectional fluorescence microscopy image of the sciatic nerve depicts binding of GE3111 to the myelin sheath (examples are indicated by yellow arrows) surrounding the nerve axon (d). A cross-sectional image of a sciatic nerve of a control animal is completely dark (e). Normalized spectra of nerve, muscle, and adipose are shown to illustrate spectral separations between tissue types (f).
that following IV injection, the inclusion complex formed between GE3111 and 2-HPβCD could limit the initial efficacy of the drug. Furthermore, the effects of inclusion complex appear to saturate at approximately 10 % 2-HPβCD as indicated by the lack of further effects in concentrations above 10 %.

Image-Guided Surgery Using the Compact Instrument Following in vivo characterization of GE3111 in mice using the commercial, small animal imaging instrumentation, we tested the feasibility of our modified compact instrument [30] for use during open surgical procedures. A dose of 3.33 mg/kg was administered to adult male CD-1 mice. The imaging system was positioned immediately above the mouse, allowing for live image capture, while an adjacent monitor displayed real-time video during the procedure. Using less than 2.5 mW/cm² excitation power of laser illumination at 405 nm laser, high brightness images of the emitted fluorescence were captured. Without administration of GE3111, no fluorescence was visible in nervous tissue. Figure 6 shows still images of control and GE3111-labeled tissue.

Discussion

Nerve trauma is a major cause of morbidity associated with several surgical procedures and can lead to post-surgical complications that could have deleterious effect on the patient's quality of life [1, 3, 7, 33–35]. A method to better visualize nerves prior to injury could improve patient outcome by reducing the risk of nerve damage.

Fluorescently conjugated nerve contrast agents have been described, including a protein fragment for labeling retrograde transport in the nerves following intramuscular administration [36], as well as peptides that target the connective tissue in the epineurium and endoneurium [39]. GE3111 and the analogs that we reported on previously [20] are small molecule distyrylbenzene dyes, which are capable of crossing the blood–brain barrier (BBB) and blood–nerve barrier (BNB) effectively. In general, small molecules are less costly to produce and may be engineered by chemical modifications to confer more appropriate characteristics such as improved pharmacokinetics, lipophilicity, and target affinity. Thus, they constitute a working base for the development of promising candidates for use in image-guided surgery.
A number of key traits must be met for the optimization of contrast agents for in vivo imaging of nerves through myelin. The fluorophore has to selectively target a component of myelin and must be capable of penetrating the BNB, which is similar in both feature and function to the BBB. Most molecules that do cross the BBB have high lipid solubility as measured by their logD’s, with values between 1 and 4 as ideal [38]. Because of this, some degree of non-specific partitioning to adipose tissue could be expected. Additionally, the molecular weight should be less than 600–700 g/mole, with 400 g/mole as ideal [39]. Therefore, the myelin-targeting moiety has to be inherently fluorescent because conjugating it to a dye could significantly increase its molecular weight beyond the desirable range.

GE3111 has a molecular weight of 405 g/mole and binds to a major component of myelin, MBP. Its optical properties in vitro support previous findings which suggested that optical properties of molecules which contain both electron donating and withdrawing groups in the same molecule can be sensitive to the local environment [20]. Its logD of 4.5 is not yet ideal, but is better than that of GE3082. The improvement in aqueous solubility resulted in easier formulation using more clinically relevant excipients and less disperse solution once formulated.

GE3111 crossed the BNB and BBB after a single IV injection and localized to central and peripheral nerves. Its kinetics of maximal uptake in the nerve was adjustable, depending on the amount of 2-HPβCD in the formulation buffer. The maximal N:M was achieved 4 h post-injection and 1 h post-injection when formulated in 30 % and 0 % 2-HPβCD, respectively. It is possible that the formation of

Fig. 5. The kinetics and overall effect of formulation on tissue-specific fluorescence. A single injection of 3.77 mg/kg GE3111 formulated in 58.5 % distilled water, 30 % 2-HPβCD, 10 % propylene glycol, 1 % PEG-300, and 0.5 % DMSO was given 1, 2, 3, 4, 12, and 24 h prior to imaging. (a) The area under the curve for the fluorescence spectrum acquired in sciatic nerve, adjacent muscle, and adipose is calculated and reported as fluorescence (n=3 mice per group). (b) The nerve-to-muscle ratio was then calculated using the total fluorescence reported in (a) as compared to adjacent muscle tissue. In a separate experiment, mice were given a dose of 3.77 mg/kg GE3111 in formulations varying in 2-HPβCD concentration (e.g., 0 %, 2 %, 10 %, or 30 %), and the images were collected 1 h post-IV administration of GE3111 (c). Tissue specific fluorescence in the sciatic nerve, adjacent muscle, and adipose (n=3 mice per group) is shown. In (d), nerve-to-muscle ratios of 3.77 mg/kg GE3111 formulated in either 0 % or 30 % 2-HPβCD and given at 1, 2, 3, and 4 h post-injection are shown (n=3 mice per group).

Fig. 6. Individual frames extracted from real-time video recorded during an open surgery using a compact instrumentation built in-house. A dose of 3.33 mg/kg GE3111 was administered to adult male CD-1 mice. The compact instrumentation was positioned immediately above the mouse. Sciatic nerve fluorescence images were acquired 4 h post-IV administration of the fluorophore (a) and compared with images from a naïve mouse receiving a control/formulation excipient only (b).
inclusion complexes between GE3111 and the internal pore of 2-HPβCD, a cyclic oligosaccharide, can slow the kinetics of the drug distribution in vivo by reducing the free-to-bound drug ratio post-IV injection [40].

Under multispectral imaging, the nerve fluorescence appeared in a different color than the adipose tissue fluorescence, which also exhibited higher fluorescence intensity. One explanation for the increase in adipose tissue fluorescence intensity is the dependence of agent optical properties with local environment. Adipose tissue is highly non-polar, with the majority of fatty acid content comprising of oleic, palmitic, and linoleic acid [41], similar to olive oil. The effect of solvent polarity (Table 2) on quantum yield and fluorescence emission could help explain the observed effect of GE3111 in adipose tissue.

The dosing and kinetics studies were performed using a commercial, small animal imaging instrument. Once the in vivo spectroscopic properties were determined, a compact, intraoperative imaging instrument was adapted accordingly for real-time imaging of GE3111-labeled nerves. The modifications on the compact device were focused on optimization for usage with GE3111. Through the use of consumer grade cameras and fiber optic delivery of laser light, we have reduced the size (~2 kg) and cost (~$10,000) of imaging instrumentation, as compared to previous clinical optical instrumentation on the order of $100,000.

Several recent works have presented the merits of fluorescence imaging in the near infrared (NIR), namely, clear spectral separation of the fluorescence and the color channels, reduction of autofluorescence, and increased penetration depth relative to excitation in the ultraviolet/visible [42, 43]. These benefits, coupled with the development of NIR fluorophores, have resulted in successful deployment of NIR instrumentation for preclinical and clinical surgical imaging. In this paper, we have described another viable approach for fluorescence imaging using visible dyes. Although illuminating the tissue at 405 nm excites autofluorescence, the relatively large Stokes shift of GE3111 allows for efficient spectral separation of the dye fluorescence from background. Additionally, the peak emission wavelength is in the green, corresponding to the peak responsivity of conventional silicon detectors, and thus higher sensitivity detection, as much as 2–3 times higher than NIR wavelengths. A potential disadvantage of visible fluorescence is that it impedes the concomitant detection of color video using white light. One way to address this is to alternate between the white light and fluorescence channels, creating a dual-mode instrument through time multiplexing. The excitation wavelength at 405 nm can then readily be removed from the optical path with minimal impact on the color video channel [44].

Conclusions

Selective contrast agents for nerve imaging, coupled with a practical implementation of instrumentation, represent a step towards clinical translation of fluorescence image-guided surgery for prevention of nerve damage. Future initiatives will focus on expanding the understanding of pharmacologic activity of GE3111, such as determining its concentration in key tissue targets through quantitative in vivo biodistribution, identifying potential metabolites, and assessing its toxicology profile using cell culture. We will also advance the imaging instrumentation towards dual-mode imaging and minimally invasive surgical procedures.

Acknowledgements. We would like to thank Joseph Greene and Eric Williams for the experimental assistance and John Frangioni and Summer Gibbs-Strauss of Beth Israel Deaconess Medical Center for the helpful discussion. This work was supported by NIBIB through NIH grant EB022872.

Conflict of Interest. The authors are employees of General Electric Company.

Open Access. This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Marien TP, Lepor H (2008) Does a nerve-sparing technique or potency affect continence after open radical retropubic prostatectomy? BJU Int 102:1581–1584
2. Michaelson MD, Cotter SE, Gargollo PC et al (2008) Management of complications of prostate cancer treatment. CA Cancer J Clin 58:196–213
3. Benson DF, McLellan D, Feng Z et al (2008) 5-Year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol 179:S40–S44
4. Walz J, Graeven M, Huland H (2007) Basic principles of anatomy for optimal surgical treatment of prostate cancer. World J Urol 25:31–38
5. Bruce J, Drury N, Poobalan AS et al (2003) The prevalence of chronic chest and leg pain following cardiac surgery: a historical cohort study. Pain 104:265–273
6. Sharma AD, Parmley CL, Sreeram G, Grocott HP (2000) Peripheral nerve injuries during cardiac surgery: risk factors, diagnosis, prognosis, and prevention. Anesth Analg 91:1358–1369
7. Mailis A, Umana M, Feindel CM (2000) Anterior intercostal nerve damage after coronary artery bypass graft surgery with use of internal thoracic artery graft. Ann Thorac Surg 69:1455–1458
8. Alfifi P, Policarpo M, Cherovec C et al (2001) Post-thyroidectomy superior laryngeal nerve injury. Eur Arch Otorhinolaryngol 258:451–454
9. Cooper DS (2008) Thyroxine monotherapy after thyroidectomy. JAMA: J Am Med Assoc 299:817–819
10. Baker D, Conley J (1979) Avoiding facial nerve injuries in rhytidectomy. Anatomical variations and pitfalls. Plast Reconstr Surg 64:781–795
11. Carpenter JS, Sloan P, Andrykowski MA et al (1999) Risk factors for pain after mastectomy/lumpectomy. Cancer Pract 7:66–70
12. Macdonald L, Bruce J, Scott NW, Smith WCS, Chambers WA (2005) Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer 92:225–230
13. Polasek EL, Katz J, Andrus CH et al (2006) Risk factors for chronic pain following breast cancer surgery: a prospective study. J Pain 7:626–634
14. Portenoy RK (2007) Overview of pain, Merck Manual
15. Kretschmer T, Heinen CW, Antoniadis G, Richter H-P, Konig RW (2009) Iatrogenic nerve injuries. Neurosurg Clin N Am 20:73–90
16. Peters T (2006) Image-guidance for surgical procedures. Phys Med Biol 51:R505–R540
17. Katahira A, Niikura H, Kailo Y et al (2005) Intraoperative electrical stimulation of the pelvic splanchnic nerves during nerve-sparing radical hysterectomy. Gynecol Oncol 98:462–466
18. Rehman J, Christ GJ, Kaynan A, Samadi D, Fleischmann J (1999) Intraoperative electrical stimulation of cavernosal nerves with
monitoring of intra-corporeal pressure in patients undergoing nerve sparing radical prostatectomy. BJU Int 84:305–310

19. Costello AJ, Brooks M, Cole OJ (2004) Anatomical studies of the neurovascular bundle and cavernosal nerves. BJU Int 94:1071–1076

20. Gibbs-Strauss S, Nasr K, Fish K et al (2011) Nerve-highlighting fluorescent contrast agents for image-guided surgery. Mol Imaging 10:91–101

21. Gelderblom H, Verweij J, Noote K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590–1598

22. Tellingen OV, Huizing MT, Panday VRN et al (1999) Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81:330–335

23. Jie J (2003) Name Reactions, 2nd Ed ed., Springer Verlag Berlin Heidelberg

24. Dabrowski M, Kubicka J, Lulinski S, Serwatowski J (2005) Halogen–lithium exchange between substituted dihalobenzenes and butyllithium: application to the regioselective synthesis of functionalized bromobenzaldehydes. Tetrahedron 61:6590

25. Maryanoff B, Reitz A (1989) The Wittig olefination reaction and modifications involving phosphoryl-stabilized carbanions. Stereochemistry, mechanism and selected synthetic aspects. Chem Rev 89:863

26. Das B, Mahalingam S, Evans T (2009) Design and synthesis of novel pinacolylboronate containing combretastatin ‘antimitotic agent’ analogues. Tett Lett 50:3031

27. Reynolds GA, Drexhage KH (1975) New coumarin dyes with rigidized structure for flashlamp-pumped dye lasers. Opt Commun 13:222–225

28. Lakowicz J (1999) Principles of Fluorescence Spectroscopy, 2nd ed. Kluwer Academics, New York

29. Riccio P, Bobba A, Romito E, Minetola M, Quagliariello E (1994) A new detergent to purify CNS myelin basic protein isoforms in lipid-bound form. NeuroReport 5:689–692

30. Wang X, Bhaumik S, Li Q, Staudinger V, Yazdanfar S (2010) Compact instrument for fluorescence image-guided surgery. J Biomed Opt 15:020509

31. Stankoff B, Wang Y, Bottlaender M et al (2006) Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci 103:9304–9309

32. Porter R, Beers M (eds) (2006) Merck manual. Merck Publishing Group, Rahway, pp 2426–2430

33. Warmuth M, Bowen G, Prosnitz L et al (1998) Complications of axillary lymph node dissection for carcinoma of the breast. Cancer 83:1362–1368

34. Kehlet H, Jensen TS and Woolf CJ (2006) Persistent postsurgical pain: risk factors and prevention. Lancet 367:1618–1625

35. Macrae WA (2008) Chronic post-surgical pain: 10 years on. Br J Anaesth 101:77–86

36. Schellingerhout D, Le Roux L, Bredow S, Gelovani J (2009) Fluorescence imaging of fast retrograde axonal transport in living animals. Mol Imaging 8:319–329

37. Whitney MA, Crisp JL, Nguyen LT et al (2011) Fluorescent peptides highlight peripheral nerves during surgery in mice. Nat Biotech 29:352–356

38. van de Waterbeemd H, Camenisch G, Folks G, Chretien JR, Raevsky OA (1998) Estimation of blood–brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 6:151–165

39. Yuan X, Taft D (2007) Advanced formulation strategies for central nervous system drug delivery. In: Williams RO, Taft DR, McConville JT (eds) Advanced Drug Formulation Design to Optimize Therapeutic Outcomes. London: Informa Healthcare, pp 303–358

40. Stella VJ, Rao VM, Zannou EA, Zia V (1999) Mechanisms of drug release from cycloextrin complexes. Adv Drug Deliv Rev 36:3–16

41. Kokatnur MG, Oalman MC, Johnson WD, Malcom GT, Strong JP (1979) Fatty acid composition of human adipose tissue from two anatomical sites in a biracial community. Am J Clin Nutr 32:2198–2205

42. Gioux S, Choi H, Frangioni J (2010) Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation. Mol Imaging 9:237–255

43. Keereweer S, Kerrebijn J, van Driel P et al (2010) Optical image-guided surgery—where do we stand? Mol Imaging Biol 13:199–207

44. Gray D, Kim E, Cotero V, Staudinger VP, Yazdanfar S, Tan Hehir C (2012) A compact fluorescence and white light imaging system for intraoperative visualization of nerves. Proc. SPIE 8214:821402